Key facts
- Alvotech is seeking U.S. approval for biosimilars to J&J's Simponi.
- Alvotech is seeking U.S. approval for biosimilars to Regeneron's Eylea.
- This is a repeat attempt by Alvotech to gain regulatory clearance for these products.
Alvotech is pursuing U.S. regulatory approval for biosimilar versions of two key pharmaceutical products: Johnson & Johnson's Simponi, used to treat autoimmune diseases, and Regeneron's Eylea, a treatment for eye conditions. This application represents a subsequent attempt by Alvotech to gain market access for these biosimilars in the United States, indicating previous efforts did not result in approval.